Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806

Author： Rincon Mercedes   Broadwater Gloria   Harris Lyndsay   Crocker Abigail   Weaver Donald   Dressler Lynn   Berry Donald   Sutton Linda   Michaelson Richard   Messino Michael   Kirshner Jeffrey   Fleming Gini   Winer Eric   Hudis Clifford   Appel Stacy   Norton Larry   Muss Hyman  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.100, Iss.3, 2006-12, pp. : 301-308

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Pilot Phase II Trial of Valspodar Modulation of Multidrug Resistance to Paclitaxel in the Treatment of Metastatic Carcinoma of the Breast (E1195): A Trial of the Eastern Cooperative Oncology Group

By Carlson Robert W.   O'Neill Anne M.   Goldstein Lori J.   Sikic Branimir I.   Abramson Neil   Stewart James A.   Davidson Nancy E.   Wood William C.  

Cancer Investigation, Vol. 24, Iss. 7, 2006-09 ,pp. : 677-681

Informa Healthcare

Access to resources Recommend Favorite

Effect of addition of paclitaxel on radiotherapy delivery and locoregional control of node positive breast cancer: Cancer and Leukemia Group B 9344

By Haffty Bruce  

The Women's Oncology Review, Vol. 5, Iss. 1, 2005-03 ,pp. : 61-62

Informa Healthcare

Access to resources Recommend Favorite

A Southwest Oncology Group Randomized Phase II Study of Doxorubicin and Paclitaxel as Frontline Chemotherapy for Women with Metastatic Breast Cancer

By Lyman Gary   Green Stephanie   Ravdin Peter   Geyer Charles   Russell Christy   Balcerzak Stanley   Thomas Budd G.   Martino Silvana  

Breast Cancer Research and Treatment, Vol. 85, Iss. 2, 2004-05 ,pp. : 143-150

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer

By Murad A.M.  

Breast Cancer Research and Treatment, Vol. 45, Iss. 1, 1997-08 ,pp. : 47-53

Springer Publishing Company

Access to resources Recommend Favorite

Lapatinib sensitizes quiescent MDA-MB-231 breast cancer cells to doxorubicin by inhibiting the expression of multidrug resistance-associated protein-1

By        

Oncology Reports, Vol. 34, Iss. 2, 2015-01 ,pp. : 884-890

Spandidos Publications

Access to resources Recommend Favorite